Exelixis, Inc. (NASDAQ: EXEL) announced that Genentech, Inc.
Exelixis, Inc. (NASDAQ:EXEL) and Ipsen announced an amendment to the exclusive collaboration and licensing agreement for the commercialization and continued development of cabozantinib, to …
Exelixis, Inc. (NASDAQ:EXEL) announced two high-level appointments designed to further strengthen the company’s public affairs and business development capabilities following the launch of …
By Brett Eversole U.S.
Insiders sell stock to diversify assets and is highly regulated and scrutinized. Insiders can only sell shares at certain times during the year, and …
Exelixis, Inc. (NASDAQ:EXEL) just announced a clinical update from ongoing trials evaluating its pipeline drug Cotellic (cobimetinib), the biotech firm-created MEK inhibitor that …
Exelixis, Inc. (NASDAQ:EXEL) announced the presentation of new data from clinical trials of cobimetinib in combination with other therapies to treat forms of advanced …
As Exelixis, Inc.’s (NASDAQ:EXEL) “impressive launch continues” for its pipeline drug Cabometyx, approved to treat second-line advanced renal cell carcinoma (RCC), the most …
Exelixis, Inc. (NASDAQ:EXEL) reported financial results for the third quarter of 2016 and provided an update on progress toward delivering upon its key 2016 …
By Dana Lyons A key gauge of biotechnology stocks is testing major trendline support presently – can it hold yet again? When this …
